Facebook page







Respiratory research feeds

Subscribe to flux Respiratory research feeds
Most Recent Articles: Respiratory Research
Mis à jour : il y a 2 heures 53 min

Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients

mer, 23/09/2020 - 02:00
Indacaterol maleate delivered with the Breezhaler® inhalation device is a long-acting β2-agonist approved for chronic obstructive pulmonary disease. In the development of a once daily, inhaled fixed dose combinat...

Long-term exposure to PM10 and NO2 in relation to lung function and imaging phenotypes in a COPD cohort

mer, 23/09/2020 - 02:00
Ambient air pollution can contribute to the development and exacerbation of COPD. However, the influence of air pollution on objective COPD phenotypes, especially from imaging, is not well studied. We investig...

Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study

mar, 22/09/2020 - 02:00
This study evaluated the efficacy, safety and tolerability of the novel inhaled phosphodiesterase-4 inhibitor CHF6001 added-on to formoterol in patients with chronic obstructive pulmonary disease (COPD).

Inflammatory phenotyping predicts clinical outcome in COVID-19

mar, 22/09/2020 - 02:00
The COVID-19 pandemic has led to more than 760,000 deaths worldwide (correct as of 16th August 2020). Studies suggest a hyperinflammatory response is a major cause of disease severity and death. Identitfying C...

Airway nitrite is increased in extremely preterm infants with bronchopulmonary dysplasia

lun, 21/09/2020 - 02:00
Bronchopulmonary dysplasia (BPD) is the most common complication of prematurity and significantly contributes to mortality and morbidity with few predictive biomarkers. Given that nitrites have been implicated...

Patterns of adaptive servo-ventilation settings in a real-life multicenter study: pay attention to volume!

lun, 21/09/2020 - 02:00
To explain the excess cardiovascular mortality observed in the SERVE-HF study, it was hypothesized that the high-pressure ASV default settings used lead to inappropriate ventilation, cascading negative consequ...

Identification of lipid biomarker from serum in patients with chronic obstructive pulmonary disease

lun, 21/09/2020 - 02:00
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the United States with no effective treatment. The current diagnostic method, spirometry, does not accurately reflect the sev...

The effect of vascular risk factor burden on the severity of COVID-19 illness, a retrospective cohort study

lun, 21/09/2020 - 02:00
Patients with cardiovascular comorbidities are at high risk of poor outcome from COVID-19. However, how the burden (number) of vascular risk factors influences the risk of severe COVID-19 disease remains unres...

Smoking-associated increase in mucins 1 and 4 in human airways

ven, 18/09/2020 - 02:00
Smoking-related chronic obstructive pulmonary disease (COPD) is associated with dysregulated production of mucus. Mucins (MUC) are important both for mucus secretion and epithelial defense. We have examined th...

Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials

jeu, 17/09/2020 - 02:00
Chronic obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation and chronic inflammation. Predicting exacerbations of COPD, which contribute to disease progression, is important...

Influence of obesity on remodeling of lung tissue and organization of extracellular matrix after blunt thorax trauma

jeu, 17/09/2020 - 02:00
Previously, it has been shown that obesity is a risk factor for recovery, regeneration, and tissue repair after blunt trauma and can affect the rate of muscle recovery and collagen deposition after trauma. To ...

Pentraxin 3 promotes airway inflammation in experimental asthma

mer, 16/09/2020 - 02:00
Pentraxin 3 (PTX3) regulates multiple aspects of innate immunity and tissue inflammation. Recently, it has been reported that PTX3 deficiency enhances interleukin (IL)-17A–dominant pulmonary inflammation in an...

Pneumothorax in COVID-19 disease- incidence and clinical characteristics

mer, 16/09/2020 - 02:00
Spontaneous pneumothorax is an uncommon complication of COVID-19 viral pneumonia. The exact incidence and risk factors are still unknown. Herein we review the incidence and outcomes of pneumothorax in over 300...

LINC01503/miR-342-3p facilitates malignancy in non-small-cell lung cancer cells via regulating LASP1

mer, 16/09/2020 - 02:00
Non-small cell lung cancer (NSCLC) is one of the major types of lung cancer, which is a prevalent human disease all over the world. LncRNA LINC01503 is a super-enhancer-driven long non-coding RNA that is dysre...

Presence of heat shock protein 47-positive fibroblasts in cancer stroma is associated with increased risk of postoperative recurrence in patients with lung cancer

lun, 14/09/2020 - 02:00
Heat shock protein 47 (HSP47), a collagen-binding protein, has a specific role in the intracellular processing of procollagen production. HSP47 expression is associated with cancer growth and metastasis in sev...

Azithromycin ameliorates sulfur dioxide-induced airway epithelial damage and inflammatory responses

jeu, 10/09/2020 - 02:00
The airway epithelium (AE) forms the first line of defence against harmful particles and pathogens. Barrier failure of the airway epithelium contributes to exacerbations of a range of lung diseases that are co...

Nrf2 protects against seawater drowning-induced acute lung injury via inhibiting ferroptosis

mer, 09/09/2020 - 02:00
Ferroptosis is a new type of nonapoptotic cell death model that was closely related to reactive oxygen species (ROS) accumulation. Seawater drowning-induced acute lung injury (ALI) which is caused by severe ox...

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies

mer, 09/09/2020 - 02:00
Navafenterol (AZD8871) is a novel, long-acting, dual-pharmacology (muscarinic receptor antagonist and β2−adrenoceptor agonist) molecule in development for chronic obstructive pulmonary disease and asthma.

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology...

mer, 09/09/2020 - 02:00
Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β2-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, ...

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator

mer, 09/09/2020 - 02:00
Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β2−agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary disease (COPD). The pharmacodynamics, safety and to...